Frederick Beddingfield III, MD, PhD is Founder, President and CEO of Sienna Biopharmaceuticals, Inc., a company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics.
Dr. Beddingfield is also a board-certified dermatologist and dermatologic surgeon and served as Chief Medical Officer of Kythera Biopharmaceuticals from 2013 until it was acquired by Allergan in 2015. He was employed at Allergan for ten years during the establishment and meteoric growth of the medical aesthetic market where he served as the Chief Medical Officer for Allergan Medical and Therapeutic Area Head, Dermatology and Aesthetics. Dr. Beddingfield led the development of premier global, market-leading brands in the dermatology and aesthetics industry, including BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, KYBELLA®, LATISSE®, ACZONE®, and RHOFADE®.
Dr. Beddingfield earned an MD Degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.
Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Aclaris Therapeutics (NASDAQ: ACRS), Ascendis Pharma A/S (NASDAQ: ASND), ProNAi Therapeutics (NASDAQ: DNAI), Carbylan Therapeutics (NASDAQ: CBYL), AirXpanders (ASX: AXP), and several private companies. He was an investor in Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG).
Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. Albert received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.
John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $1B in assets under management.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of Zoomi, Inc., is currently a member of the board of directors for Zoomi, Inc. and for Brickell Biotech, Inc., has been a trustee of the Morristown Medical Center Foundation, and serves on the Advisory Council for the Keller Center of entrepreneurship at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.
Dr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.
In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.
Dr. Tina S. Alster is the founding director of the Washington Institute of Dermatologic Laser Surgery and is a clinical professor of dermatology at Georgetown University Medical Center in Washington, DC. She received her B.S. and M.D. degrees with highest honors from Duke University and completed her dermatology residency at Yale University. She is a world-recognized leader in dermatologic laser surgery and has published over 250 peer-reviewed articles, 50 book chapters and 8 textbooks on the subject. Her contributions have resulted in her being honored with the Women’s Dermatologic Society mentorship and legacy awards, American Society for Dermatologic Society service award and the Leon Goldman award from the American Society for Medicine and Surgery, among others. Dr. Alster maintains leadership and board positions in numerous professional and national organizations. Her commitment to teaching and mentoring others is evident in her establishment of scholarship endowments for women pursuing careers in medicine at Duke University. Dr. Alster has served as the consulting dermatologist to Lancôme and an advisor to La Mer. She developed her own skin care line “Skin Is In” in 2011. Her contributions to the field have been acknowledged by listings in America’s Best Doctors, Town & Country’s Best Cosmetic Surgeons, America’s Elite 1000, Allure’s Influencer of the Year, Elle Genius Awards and Washingtonian’s Best Doctors. She has also appeared on national and international TV and radio shows, including Oprah, Today Show, CNN, Daily Show with Jon Stewart, 20/20, and Discovery Channel. She has been listed by US News & World Report as among the nation’s top 1 percent of physicians in dermatology.
Wilma Fowler Bergfeld, MD, FACP is Emeritus Director, and past Director and Co-Director of Dermatopathology, Departments of Dermatology and Pathology and Senior Staff Dermatologist Dermatological Research in the Department of Dermatology, Cleveland Clinic. She also is the Director of the Cleveland Clinic’s Dermatopathology Fellowship and Professor of Dermatology and Pathology, Cleveland Clinic Educational Foundation and Associate Clinical Professor, Department of Dermatology, Case Western Reserve University. She has served as a consultant to the Department of Sports Medicine at The Cleveland Clinic. Dr. Bergfeld’ s specialty interests include clinical dermatology (hair disorders, androgen excess, photo aging, and cosmetic dermatology) and dermatopathology.
Dr Bergfeld completed her undergraduate work at the College of William and Mary in Williamsburg, VA, and is a graduate of Temple University School of Medicine in Philadelphia. She did her dermatology residency at Cleveland Clinic and her Dermatopathology fellowship at Armed Forces of Pathology in Washington DC. She joined the Cleveland Clinic in 1969 as a Clinical Dermatologist, Department of Dermatology and later, after the AFIP Dermatopathology Fellowship in 1972, she was appointed as Head (1977-2007), Dermatopathology, Department of Pathology and in 2007 Co-Director of Dermatopathology, Departments of Dermatology and Pathology and in 2015 Emeritus Director . She has been the Director, Cleveland Clinic’s Dermatopathology fellowship since 1975.
Dr. Bergfeld is a former chair and currently consultant to the FDA Dermatology and Ophthmology Advisory Committee (1972-current) and more recently a consultant to the Devise advisory committee (2009-current). She is the current President of North American Hair Research Society (2011-2016) and Director, World Congress of Hair Research2015 Miami, and past 2008-9 President of the American Society of Dermatopathology, 1992 President of The American Academy of Dermatology and past President of the Cleveland Academy of Medicine, the Cleveland Dermatology Society, the Ohio Dermatological Association, and the Women's Dermatological Society. She has served on the Cleveland Clinic’s Board of Governors and Board of Trustees (1992-97), and was the President of the Cleveland Clinic Staff (1990).
Since 1977, she has been a member and the Chair (1990-current) of the Cosmetic Ingredient Expert Panel, an expert panel that determines the safety of cosmetic ingredients. She holds an honorary membership in the American Academy of Dermatology, Women’s Dermatology Society, the Cleveland Dermatology Society, Ohio Dermatological Society, Pacific Dermatologic Association the Canadian Dermatology Society and the Italian Dermatology Society.
In 1996, she received the Women's Dermatological Association Rose Hirschler Award honoring an outstanding physician who has contributed to medicine and dermatology while enhancing the role of women in the Dermatology. She received the American Academy of Dermatology's prestigious Marion B. Sulzberger Award in 1997 and was the recipient of the AAD Golden Triangle Award 2000 for Community Service. In 2000, she was the first recipient of the Wilma F Bergfeld MD Leadership Award, presented by the Women’s Dermatology Society. In 2005, the Cleveland Academy of Medicine awarded her the “John Budd, MD, Distinguished Member Award. The American Society Dermatopathology in 2007 awarded her the prestige’s “Founders Award” and she was elected 2009 President of the American Society of Dermatopathology. In 2008 she was awarded Maria Duran leadership award and medal by the International Society of Dermatology and in 2010; she received the Samuel J Zakon Dermatology History Award from the Dermatology History Society. The American Academy of Dermatology awarded her 2012 Master of Dermatology Award.2014 she received the Elston B. Helwig MD, Memorial Award and Lectureship.
Her American Academy of Dermatology volunteer activities have included: Chair, Council of Communications and long time member of the communications committee, original member and long term member of “Dialogues in Dermatology,” Chair of the Scientific Council (annual meeting committee), Chair of the Volunteer Circle: “Members Making a Difference.” She has also served on several AAD and Women’s Dermatology Society Visionary Committees. Dr Bergfeld has received many AAD Presidential citations that have included Leadership in AAD Communications and The Volunteer Circle. Since 1995, she has been cited in “Best Doctors in America,” “Top Doctors,” “Top Pathologist,” and in numerous Who’s Who publications.
Dr Bergfeld is the author of over 600 publications, 4 books and 80 book chapters. She has served on many editorial journal boards and has been a reviewer in the both her professional fields of clinical dermatology and dermatopathology. Other activities include consultant/scientific adviser to many pharmaceutical companies.
Lynn A. Drake, MD, is Lecturer at Harvard Medical School, on the Dermatology Faculty at Massachusetts General Hospital (MGH) and is Director of Policy and Business Development for the Wellman Center of Photomedicine at MGH in Boston. She has a Doctor of Medicine (MD) degree, a Master of Arts (MA) degree in Mathematics, a Bachelor of Arts (BA) degree in Mathematics, and a Bachelor of Arts (BA) in Chemistry. She is board certified in Dermatology and Dermatopathology. Dr. Drake is a graduate of the Advanced Management Program (AMP) at Harvard Business School and devoted her sabbatical year to the study of medicine and business. Dr. Drake is Past President of the American Academy of Dermatology and the Women’s Dermatology Society. She has served on the National Advisory Board for the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), the Board of Directors of the American Society of Dermatologic Surgery, and as a Robert Wood Johnson Health Policy Fellow and Congressional Fellow in Washington, DC, sponsored by the Institute of Medicine. She received a Presidential Appointment as a US Delegate to the World Health Organization and was on the National Policy Forum Council for Health Care Reform. She has also served as a Trustee for the Dermatology Foundation and on the Board of Directors for the Council for Nail Disorders and the American Acne and Rosacea Society. Dr. Drake previously served as Professor and Chair of the Department of Dermatology at University of Oklahoma Health Sciences Center, and Deputy Chair of the Department of Dermatology at Harvard Medical School where she was also Director of the Dermatology Clinical Investigation Unit. She has been on the faculty of Emory University, was a partner in the Emory Clinic, and served as Chief of the Dermatology Service at the VA Medical Center in Atlanta. She currently Chairs the Food and Drug Administration’s (FDA’s) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) at the Center for Drug Evaluation and Research (CDER), is a consultant to the FDA, and has served on multiple FDA Advisory Board panels.
Dr. Drake was named as one of the 100 Best Doctors in America, Outstanding Young Women of America, and received the Outstanding Alumnus Award from the University of Tennessee College Of Medicine and the Outstanding Alumnus Achievement Award from Adams State University in Colorado where she was invited to deliver the commencement address in 2009. Dr. Drake received the Bergfeld Award for Leadership and Vision and the Rose Hirschler Award from the Women’s Dermatologic Society. She was elected to membership in the American Dermatological Association and has received honorary membership in the German, Canadian, and Mexico Dermatological Society(s). She is recipient of several named lectureships, is the author of over 100 papers, and has been a visiting professor at over 60 universities. She has presented over 400 invited national and international lectures and has been a frequent contributor to multiple media sources.
Barbara A. Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS) respectively. After a post-doctoral fellowship in the laboratory of Howard Green at MIT, Dr. Gilchrest joined the Department of Dermatology and Division on Aging at the HMS, where she established a tissue culture laboratory to study the aging process in human skin, with support from the National Institute on Aging (NIA). From 1985 until 2008, Dr. Gilchrest served as Professor and Chairman of Dermatology at the Boston University School of Medicine, where she directed a large laboratory and an NIH-sponsored post- doctoral research training program. Her laboratory studied cellular aging, regulation of melanogenesis, and telomere-based protective responses in the skin; complementary clinical research interests focused on therapeutic uses of light in dermatology. She remained as Professor on a part-time basis until 2014 while serving as Editor-in-Chief for the Journal of Investigative Dermatology (2012-17). In 2015 she joined the Department of Dermatology at the Massachusetts General Hospital and Harvard Medical School.
Dr. Gilchrest is the author of over 400 scholarly articles, reviews, abstracts, and textbook chapters; and author or editor of eight books. She has served in leadership positions for all the major dermatologic organizations; on the National Advisory Council on Aging and the Board of Scientific Counselors of the National Cancer Institute; as associate editor or editorial board member of several major clinical and research journals; as a consultant or scientific advisory board member for pharmaceutical and biotechnology companies; and as a member of the MIT Corporation (1995-2005). Dr. Gilchrest is a Fellow of the American Association for the Advancement of Science, an elected member of the National Academy of Medicine, and a Charter member of the National Academy of Inventors.
Dr. Gottlieb is an internationally recognized expert and leader in the field of psoriasis and psoriatic arthritis and related disorders. She is currently Professor of Dermatology at New York Medical College.. From March, 2006 until May 11, 2016, she was at the Tufts Medical Center as its Chair of Dermatology and Dermatologist-in-Chief of the hospital. She is the former Professor of Medicine and Founding Director of the Psoriasis Center of Excellence at UMDNJ-Robert Wood Johnson Medical School. Her research, using targeted immunobiologics as pathogenic probes, provided new understanding of the pathogenesis of psoriasis and provided the foundation for biologic drug development in psoriasis and psoriatic arthritis. Her translational research provided the first double blind, randomized, placebo-controlled study of the efficacy of TNF blockers as monotherapy for moderate to severe psoriasis (published in Lancet in 2001). This work led to multiple TNF blockers being FDA-approved for psoriasis. TNF blockers have revolutionized the care of psoriasis and psoriatic arthritis patients.
Dr. Gottlieb has authored over 300 peer-reviewed articles that have appeared in journals such as The Lancet, the New England Journal of Medicine, Nature: Drug Discovery, Proceedings of the National Academy of Sciences, Journal of Experimental Medicine, Archives of Dermatology, the Journal of the American Academy of Dermatology, and Journal of Investigative Dermatology. She has presented her research at more than 200 dermatology and rheumatology conferences in Europe, Asia and the United States, as well as at the FDA and the National Academy of Sciences. She is on almost every list of outstanding doctors, including Best Doctors in America and Best Doctors in Boston. She is triple boarded in dermatology, rheumatology and internal medicine, and is one of only a handful of doctors in the United States to be certified in all three of these specialties.
Dr. Gottlieb has received numerous awards for mentoring and teaching including multiple Excellence in Teaching Awards from the Department of Dermatology at Tufts University Medical School/Tufts Medical Center, Honorary Membership in Alpha Omega Alpha in recognition of medical student teaching, a Research Mentorship award from the Internal Medicine house staff and a Mentorship Award from the American Chemical Society for mentoring minority high school students in bench and clinical research She is also the recipient of the 2016 National Psoriasis Foundation’s Outstanding Educator in Psoriatic Disease Award.
Dr. Gottlieb was elected to the Board of Directors of the American Academy of Dermatology for 2011-2015. Dr. Gottlieb is a member of the American Dermatological Association and Noah Worcester Dermatology Society amongst other professional societies. She is the founder and President of the International Dermatology Outcome Measures (IDEOM) group. This consortium of patients, physicians, pharmaceutical scientists and other stakeholders is dedicated to bringing clinically practical outcome measures to dermatologic practice that satisfy the needs of all stakeholders.
Dr. Gottlieb was one of the first scientists to demonstrate that psoriasis is a T cell mediated disease. She initially demonstrated increased numbers of activated T cells and increased expression of a number of immunologic cytokines in psoriatic plaques (reported in multiple publications, e.g., the Journal of Experimental Medicine, Proceedings of the National Academy of Sciences). She then showed that treatment with a T cell-specific immunotoxin cleared psoriasis clinically and histologically (published in Nature Medicine and noted in commentary in The Lancet). Dr. Gottlieb, through her published studies and public presentations, has convinced a number of pharmaceutical companies to use psoriasis as their proof-of-concept disease when testing new immunomodulators that may decrease T cell and dendritic cell cytokine production. Thus, her work has affected drug development in psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and transplantation. As a direct result of Dr. Gottlieb’s work, many biotechnology-engineered immunomodulators are FDA and /or EMEA-approved for psoriasis and psoriatic arthritis. In 2001, she received the American Skin Association’s Psoriasis Research Award in recognition of her work. In 2006, she received the Honorary Fellowship Award of the American College of Clinical Pharmacology. Currently, Dr. Gottlieb’s research centers on developing new treatments for psoriasis and psoriatic arthritis, developing better outcome measures for psoriasis and on understanding the mechanisms of action of these novel agents. Additionally, she is working on initiatives to prevent disability due to psoriatic arthritis and to develop outcome measures useful to all stakeholders and useful in clinical practice.
Dr. Gottlieb obtained her MD from Cornell Medical School and her PhD in Immunology from the Rockefeller University, where she studied in the laboratory of Henry Kunkel and was one of the first females admitted to Rockefeller University/Cornell University School of Medicine’s joint MD-PhD program. She has also been a leading educator in her specialties, and has been on the forefront of mentoring female and minority students and overseeing community outreach and patient advocacy programs. She is active in the autoimmune disease community as a councilor of the International Psoriasis Council and a member of the Executive and Steering Committees of GRAPPA (an international psoriatic arthritis coalition), Medical Advisory Board member and Co-Editor of the Journal of Psoriasis and Psoriatic Arthritis, the physicians’ newsletter of the National Psoriasis Foundation. She was a member of the Board of Directors of the American Academy of Dermatology. In 2016, she was awarded Honorary Membership in the American Academy of Dermatology for her outstanding leadership and service, and sustained dedication to dermatology and the goals and mission of the Academy.
Dr. Gary P. Lask is currently Clinical Professor and the Director of Dermatologic Surgery and the Dermatologic Laser Center at the David Geffen School of Medicine at UCLA. He has held similar positions at Harbor-UCLA Medical Center and Jefferson Medical College. He has co-edited four textbooks: Aesthetic Dermatology, Principles and Practices of Cutaneous Surgery, Lasers in Dermatology and Cosmetic Surgery, and Comprehensive Aesthetic Rejuvenation: A Regional Approach. He is founding editor of the Journal of Cutaneous Laser Therapy. He headed one of the eight investigation sites for the original pulsed dye laser and subsequently was one of three investigational sites for the second generation longer pulsed dye laser. He co-authored one of the original publications on the early treatment of capillary hemangiomas with the pulsed dye laser and one of the first publications on the use of the CO2 laser for the treatment of photodamage and rhytides. He was selected by The Best Doctors of America and is featured in the national directory of Who’s Who in Executives and Professionals.
Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed residencies in internal medicine and dermatology, both at Mount Sinai.
Dr. Lebwohl has been practicing dermatology since 1983. He is professor and chairman of the Department of Dermatology of The Icahn School of Medicine at Mount Sinai. Dr. Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine. Dr. Lebwohl was the American Academy of Dermatology President in 2015-16.
Dr. Lebwohl is Chairman Emeritus of the Medical Board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum and is on the editorial boards of the Journal of the American Academy of Dermatology and the Journal of Skin Cancer. He is also editor of the Dermatology Section of Scientific American Medicine. Dr. Lebwohl has chaired numerous symposia and has written, edited, or co-edited several books including the first atlas devoted entirely to cutaneous manifestations of systemic disease, and the leading book on dermatologic therapy, Treatment of Skin Disease which is now in its 5th edition. The second edition of The Skin and Systemic Disease has been published in English and in French, and English, Portuguese, Chinese and Polish versions of Treatment of Skin Disease have been published. Other books include Difficult Diagnoses in Dermatology, Psoriasis,Mild-to-Moderate Psoriasis and Moderate-to-Severe Psoriasis. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments. He has authored or co-authored over 500 publications including peer-reviewed articles, invited articles and book chapters.
Dr. Lebwohl has received numerous awards for teaching, research, mentorship and service from the Mount Sinai School of Medicine, the American Academy of Dermatology, the National Psoriasis Foundation, PXE International, the American Skin Association, the Journal of Drugs in Dermatology, the Royal Society of Medicine, and the President’s Council on Service and Civic Participation.
Ken Washenik, MD, PhD, is the Chief Executive Officer and Medical Director of the Bosley Medical Groups, the world’s largest hair restoration practice, and the former Chief Executive Officer of the Aderans Research Institute, a biotechnology firm involved in researching tissue engineered hair follicle neogenesis and cellular based hair restoration.
Dr. Washenik is the Immediate-Past President and a Board member of the North American Hair Research Society and Vice Chair of the Board of Trustees of the Hair Foundation. He is also the Treasurer, a Fellow and on the Board of Governors of the International Society of Hair Restoration Surgery, and a Board member of the Cicatricial Alopecia Research Foundation, as well as a member of the American Academy of Dermatology and the medical honor society, Alpha Omega Alpha. He is a Diplomate of the American Board of Dermatology and a member of the Dermatological Society of Greater New York and the Los Angeles Metropolitan Dermatological Society.
The former director of the Dermatopharmacology Unit at the New York University School of Medicine, Dr. Washenik continues to serve as a faculty member in the Department of Dermatology. In 2014, he was the recipient of the Platinum Follicle Award from the International Society of Hair Restoration Surgery.
Dr. Washenik, a well-known national and international lecturer, has presented many seminars on hair growth and loss, dermatopharmacology, and dermatology-related issues. His Doctor of Philosophy (PhD) degree is in Cell Biology and focused on hormone metabolism.
Dr. Washenik has published numerous scientific and medical articles in peer-reviewed journals including Endocrinology, Journal of the American Academy of Dermatology, Archives of Dermatology, The Lancet, and the New England Journal of Medicine.
Angela joined Dermira in 2015 and serves as Vice President of Patient Value. Angela has nearly 20 years of biotech and pharmaceutical experience with the majority of time focused in the dermatology therapeutic and consumer market. Prior to Dermira, Angela served as Vice President, Medical Relations at SkinCeuticals, a L'Oréal company. She has held various leadership roles in medical relations, sales, marketing and business development at organizations including L'Oréal, Stiefel, Connetics, Indevus, Inc., Johnson & Johnson and Alza. She is a member of numerous associations including the American Academy of Dermatology, Women's Dermatologic Society, American Society for Laser Medicine & Surgery, National Psoriasis Foundation, Acne & Rosacea Society and the Healthcare Businesswomen's Association. She has served on the Industry Advisory Council for the American Society for Dermatologic Surgery.
Angela earned a B.S. in marketing and business administration from Limestone College.
Alex Martin joined Realm Therapeutics in June 2015 as Chief Executive Officer and Executive Director. He brings nearly 30 years of experience as a senior executive in private and public biopharmaceutical companies. He previously served as Chief Executive Officer of Affectis Pharmaceuticals AG, Chief Operating Officer of Intercept Pharmaceuticals (NASD: ICPT), and Chief Financial Officer at BioXell S.p.A., which was acquired by Cosmo Pharmaceuticals S.A. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals before joining Novartis as Vice President, Global Business Development & Licensing. Most recently, he served as President of moksha8, a leading Latin American specialty pharmaceutical company. In his various roles, he has built teams, raised multiple rounds of capital and closed transformative deals with world-class companies. Mr. Martin holds a BA from Cornell University and an MBA from The Harvard Business School.
Mr. Partridge brings marketing and communications experience spanning more than 20 years in the pharmaceutical industry to the CLS team. It marks the third major pharmaceutical effort headed up by Robert J. Bitterman, Sr., of which he's been a part. He earned separate degrees in Business Administration/Marketing and International Politics, and has an extensive track record of successful messaging and positioning of brands and promotional campaigns both in and outside of U.S. markets. He has been a key member of launch and pre-launch teams for Sanofi-Aventis companies in the fields of oncology, hematology, and neurology prior to moving into dermatology in 1996. He led the launch of the first monoclonal antibody purified factor VIII replacement product, and worked on the pre-launch of Rhone-Poulenc Rorer's lead chemotherapy product in the U.S., Taxotere. He also was part of the launch team for the first and only product approved by the FDA to treat amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease. His work also included a joint project with Dr. Jonas Salk's 'Immune Response Corporation' which at the time was attempting to develop a successful vaccine for HIV.
Within the dermatology specialty Mr. Partridge has experience with both medical and cosmetic product launches from a marketing and public relations perspective. He is the past Chairman for the Board of Directors of the Greater West Chester (PA) Chamber of Commerce. He also sits on two other non-profit Boards in the Southeastern Pennsylvania region, for the Franklin Mint Federal Credit Union with assets over $1 billion, and the West Chester Area Education Foundation.
Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline’s Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.
N. Nicole Stakleff is a partner with Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney since 2002, Ms. Stakleff concentrates her practice in intellectual property law, including strategic patent prosecution and counseling and due diligence in the pharmaceutical, chemical, medical and other life sciences fields.
Dr. Shiv Taylor is a Senior Managing Director in the Healthcare Investment Banking group at Guggenheim. He focuses on Biotechnology and Pharmaceutical companies. Prior to joining Guggenheim, he was at Deutsche Bank in the Healthcare Investment Banking group. Prior to investment banking, Dr. Taylor was Head of Healthcare Investments at Plainfield Asset Management and a General Surgery Fellow at Harvard Medical School, Beth Israel Deaconess Medical Center.
Jean-Jacques is President & CEO of Pierre Fabre Dermatologie (PFD), a global brand dedicated to Medical Dermatology operating in 80 countries. PFD is a brand from Pierre Fabre Group, a 2,3 B€ french pharma company, known for its expertise in dermatology, dermo-cosmetics and oncology.
Since he joined PFD in Nov.2003, and before being appointed President & CEO of PFD in 2013, Jean-Jacques has held several positions in PFD (Head of Medical Affairs, Head of Marketing/Development, Head of the French Subsidiary where PFD lead the market in terms of drug prescriptions by dermatologists). PFD is amongst the Top 10 global companies in Medical Dermatology in the world.
Jean-Jacques has led the worldwide development of Hemangiol, the first and only oral solution of propranolol specifically designed for safe and effective use in infants with Infantile Hemangiomas requiring systemic therapy (orphan condition). The development included an innovative phase II/III clinical trial, with results published in New England Journal of Medicine in 2015. Hemangiol is currently approved in 34 countries (EU, USA, Switzerland, Australia), with many other approvals expected in the coming years. Hemangiol was awarded "Drug of the year in 2014 in France" by the Prix Galien. Currently, PFD focus its R&D efforts in Orphan skin diseases, Pediatric Dermatology and Dermato-Oncology.
Prior to joining Pierre Fabre, Jean-Jacques was General Manager for Aster Dermatologie, a french CRO fully dedicated to the clinical evaluation of dermo-cosmetic products and drugs in dermatology, where he had the opportunity to conduct clinical trials for major companies in dermatology. Jean-Jacques is a board certified dermatologist and was trained in Bordeaux (France).
Warren J. Winkelman, MD, PhD, MBA, FAAD, FRCPC is Senior Medical Director and Head of Medical Innovation for the Nestlé Skin Health Investigation, Education and Longevity Development (SHIELD) Center in New York. SHIELD, launched in December 2014, is a global network of innovative cross-discipline experts and visionaries working every day to develop new approaches in skin health, nutrition and wellness in this era of unprecedented longevity.
Warren holds a PhD in ehealth innovation, health policy, management and evaluation from the University of Toronto and an MBA in healthcare administration from SUNY-Binghamton School of Management. He was awarded a Canadian Institutes of Health Research (CIHR) fellowship in ehealth innovation science, and has conducted research under the auspices of the Center for Global eHealth Innovation (Toronto), the Canadian Dermatology Foundation (CDF) and the National Research Council-Canada (NRC) to help promote the empowerment of patients living with chronic skin disease and their caregivers through information and communication technologies.
Warren is a board-certified dermatologist with more than 25 years' experience in patient care, medical education, research, and has held medical leadership roles at Schering-Plough, Merck, Janssen and Galderma. He is a graduate of the Sophie Davis School of Biomedical Education at City College of New York, receiving his MD from the State University of New York (SUNY) at Buffalo School of Medicine and Biomedical Sciences, and completing his dermatology residency at McGill University.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.